Percutaneous Pulmonary Valve Implantation in Humans
Results in 59 Consecutive Patients

Sachin Khambadkone, MD, MRCP*; Louise Coats, MRCP*; Andrew Taylor, MD, MRCP, FRCR*;
Younes Boudjemline, MD; Graham Derrick, MRCP; Victor Tsang, MD, FRCS; Jeffrey Cooper, SCST;
Vivek Muthurangu, MRCPCH; Sanjeet R. Hegde, MRCPCH; Reza S. Razavi, MD, MRCPCH;
Denis Pellerin, MD, PhD; John Deanfield, FRCP; Philipp Bonhoeffer, MD

Background—Right ventricular outflow tract (RVOT) reconstruction with valved conduits in infancy and childhood leads to reintervention for pulmonary regurgitation and stenosis in later life.

Methods and Results—Patients with pulmonary regurgitation with or without stenosis after repair of congenital heart disease had percutaneous pulmonary valve implantation (PPVI). Mortality, hemodynamic improvement, freedom from explantation, and subjective and objective changes in exercise tolerance were end points. PPVI was performed successfully in 58 patients, 32 male, with a median age of 16 years and median weight of 56 kg. The majority had a variant of tetralogy of Fallot (n=36), or transposition of the great arteries, ventricular septal defect with pulmonary stenosis (n=8). The right ventricular (RV) pressure (64.4±17.2 to 50.4±14 mm Hg, P<0.001), RVOT gradient (33±24.6 to 19.5±15.3, P<0.001), and pulmonary regurgitation (PR) (grade 2 of greater before, none greater than grade 2 after, P<0.001) decreased significantly after PPVI. MRI showed significant reduction in PR fraction (21±13% versus 3±4%, P<0.001) and in RV end-diastolic volume (EDV) (94±28 versus 82±24 mL·beat⁻¹·m⁻², P<0.001) and a significant increase in left ventricular EDV (64±12 versus 71±13 mL·beat⁻¹·m⁻², P=0.005) and effective RV stroke volume (37±7 versus 42±9 mL·beat⁻¹·m⁻², P=0.006) in 28 patients (age 19±8 years). A further 16 subjects, on metabolic exercise testing, showed significant improvement in VO₂max (26±7 versus 29±6 mL·kg⁻¹·min⁻¹, P<0.001). There was no mortality.

Conclusions—PPVI is feasible at low risk, with quantifiable improvement in MRI-defined ventricular parameters and pulmonary regurgitation, and results in subjective and objective improvement in exercise capacity. (Circulation. 2005; 112:1189-1197.)

Key Words: regurgitation ■ pulmonary valve insufficiency ■ magnetic resonance imaging ■ exercise testing ■ catheterization

Received November 23, 2004; revision received May 8, 2005; accepted May 10, 2005.
From Great Ormond Street Hospital (S.K., L.C., A.T., Y.B., G.D., V.T., J.C., J.D., P.B.); London Cardiac MR Research Group, Division of Imaging Sciences, Kings College and Guy’s Hospital (V.M., S.R.H., R.S.R.); and Heart Hospital (D.P.), London, UK.
*The first 3 authors contributed equally to this work.
Correspondence to Dr Sachin Khambadkone, Consultant Cardiologist, Great Ormond Street Hospital, London WC1N 3JH, UK. E-mail kambah@gosh.nhs.uk
© 2005 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org
DOI: 10.1161/CIRCULATIONAHA.104.523266

1189
blood pressure. The RVOT gradient was calculated from the velocity across the RVOT. Color flow mapping of the RVOT and branch pulmonary arteries was used to grade the pulmonary regurgitation. This was graded into 5 categories: 0, absent; 1, trivial; 2, mild; 3, moderate; and 4, severe or free pulmonary regurgitation. Any regurgitation more than grade 2 was defined as significant for the purpose of this study.\textsuperscript{15}

On the basis of RVOT gradient during cardiac catheterization, we characterized patients into 2 subgroups: gradient of \( \geq 30 \) mm Hg (Stenosis group) and gradient \(< 30 \) mm Hg (Regurgitation group).

We excluded patients \(< 5 \) years of age or weighing \(< 20 \) kg. Other exclusion criteria were pregnancy, occluded central veins, active infection, and outflow tracts with “unfavorable” morphology (narrowest RVOT diameter \(< 22 \) mm on angiography and conduits \(< 16 \) mm in diameter at surgical insertion, as described in the operation notes).

After a detailed history and physical examination, patients were assigned to a New York Heart Association (NYHA) functional class.

The design of the valved stent and technique of delivery have been reported previously.\textsuperscript{8} Under general anesthesia, vascular access was achieved through the femoral (\( n = 57 \)) or right internal jugular (\( n = 2 \)) route. Standard right heart catheterization with invasive systemic arterial pressure monitoring was undertaken for hemodynamic assessment. Angiography was used to determine anatomy of the RVOT and branch pulmonary arteries so as to determine feasibility, select appropriate site of deployment, and aid the choice of delivery system. Orthogonal projections were used, wherever appropriate, to obtain the dimensions of the RVOT, and projections were selected depending on RVOT morphology. Multitrack catheters with platinum image bands (placed 10 mm apart) were used for angiography and calibration of measurements. Hemodynamic measurements and angiography were repeated after valve implantation. After the procedure, echocardiography was performed within 24 hours to assess hemodynamics and evaluate pulmonary regurgitation. Chest radiography was performed in the frontal and lateral projections to look for stent fractures.

### Magnetic Resonance Imaging

MRI was performed at 1.5 T with 2 MR scanners (Symphony; Siemens Medical Systems, Erlangen, Germany; and Intera; Philips Medical Systems, Best, the Netherlands).

#### Assessment of Ventricular Volumes and Function by Use of Cine MRI

Retrospective gated steady-state free precession (SSFP) cine MR images of the heart were acquired in the vertical long-axis, 4-chamber view and the short-axis view covering the entirety of both ventricles (9 to 12 slices).\textsuperscript{16} Cine imaging of the RVOT in 2 long-axis planes was also performed for subsequent positioning of through-plane pulmonary flow quantification (Figure 1).\textsuperscript{16} Images were acquired during a single breath-hold. The cine SSFP sequence parameters were as follows: TR, 3.4 to 3.8 ms; TE, 1.7 to 1.9 ms; flip angle, 60 to 65°; slice thickness, 5 to 8 mm; matrix, 128 to 192\texttimes{}256; field of view, 300 to 380 mm; and temporal resolution, 25 to 40 phases.

### MR Flow Quantification

Pulmonary artery (PA) flow data were acquired by use of a flow-sensitive gradient-echo sequence (TR, 9 ms; TE, 5 ms; flip angle, 15°; slice thickness, 5 to 7 mm; and matrix, 128 to 192\texttimes{}256) during free breathing. A phase correction filter was used to correct for phase errors introduced by eddy currents and Maxwell terms. Image planes were located at the midpoint of the main PA/conduit before PPVI and just above the stent after PPVI to avoid any stent artifact (Figure 1). Through-plane flow data (40 phases per cardiac cycle) were acquired by use of retrospective cardiac gating. The velocity-encode peak velocity was varied according to degree of main PA/conduit stenosis.

Assessment of left ventricular (LV) and RV volumes was performed by manual segmentation of short-axis cine images with endocardial outline at end diastole and end systole (Argus; Siemens Medical Systems, Erlangen, Germany; or Easy Vision; Philips Medical Systems, Best, the Netherlands). End-diastolic and end-systolic volumes were calculated by use of Simpson’s rule for each ventricle, and from these volumes, stroke volume (SV) and ejection fraction (EF) were calculated. Where pulmonary regurgitation was present, an effective RVSV was calculated to reflect the net forward blood flow into the pulmonary arteries as follows: effective RVSV=RVSV\textendash{}pulmonary regurgitation volume.

Pulmonary blood flow was calculated from phase contrast images by use of a semiautomatic vessel edge-detection algorithm (Argus; Siemens Medical Systems, Erlangen, Germany; or Flow; Medis, the Netherlands) with operator correction. Pulmonary regurgitant (PR) fraction was calculated as percent backward flow over forward flow.

All volume and flow measurements were indexed for body surface area and expressed in mL \cdot beat\textsuperscript{\textendash{}1} \cdot m\textsuperscript{2}.

### Objective Assessment of Exercise Capacity: Metabolic Exercise Testing

Cardiopulmonary exercise testing was performed on a mechanically braked bicycle ergometer (Ergoline 900) with respiratory gas exchange analysis (Medgraphics, St Paul, Minn), on the same day as the pre- and post-PPVI MR studies. A ramp protocol comprising an initial period of loadless cycling to permit equilibration was used. A period of active recovery (slow cycling) was commenced after maximal exertion. Heart rate, blood pressure, and oxygen saturation were monitored in all subjects for the duration of the test.

Peak oxygen uptake (\( \dot{V}O_{2} \text{max} \)) and anaerobic threshold were derived from respiratory gas analysis during maximal exercise testing. Anaerobic threshold was determined by use of the modified V-slope method. Peak heart rate, blood pressure, and workload (watts) achieved were recorded.

### Statistical Analysis

Descriptive data are presented as medians with interquartile range and mean\( \pm SD \). Student’s paired \( t \) test was used to evaluate the difference after intervention, and a 2-tailed probability value of \( P<0.05 \) was considered significant. Categorical variables were compared by use of the \( \chi^{2} \) test, the Wilcoxon signed-rank test, and the Mann-Whitney \( U \) test. Survival curves for freedom from surgical
Results
Between January 2000 and September 2004, we attempted PPVI in 59 patients (32 male), with successful implantation in 58. One patient, in whom we failed to maneuver the valve-stent assembly into the outflow tract, is awaiting a further attempt.

Demographics and Patient Characteristics
The median age was 16 years (range, 9 to 43 years) and median weight 56 kg (25 to 110 kg); 36 patients (61%) had variants of tetralogy of Fallot, the majority of them with pulmonary atresia (n=18), 3 with absent pulmonary valve syndrome, and the rest with severe pulmonary stenosis. Most patients had a homograft conduit after surgery on the RVOT (46/59, 78%). Only 3 patients had a “native” RVOT that had been augmented with a pericardial or homograft patch (Table 1).

Immediate Hemodynamic Results
After valve implantation, the RV systolic pressure (64.4±17.2 to 50.4±14 mm Hg, P<0.001) and outflow gradient (33±24.6 to 19.5±15.3, P<0.001) (Figure 2) fell significantly. PA diastolic pressure (9.9±3.7 to 13.5±5.3 mm Hg, P<0.001) increased. Angiography showed significant improvement in regurgitation, with no patient having more mild regurgitation after the procedure (Figure 3).

In the Stenosis group, there was a significant drop in RV systolic pressure (71±15.3 to 52.3±14.5 mm Hg, P<0.001) and RVOT gradient (44.6±24.3 to 24.4±15.2 mm Hg, P<0.001). Furthermore, there was a significant drop in RV end-diastolic pressure (11.7±3.4 to 10±3.9 mm Hg, P=0.018).

In the Regurgitation group, however, there was no change in these parameters immediately after valve implantation (RV systolic pressure, 49.4±10.5 to 47.2±14.1 mm Hg, P=0.45; RVOT gradient, 14.5±9.3 to 11.8±12.1 mm Hg, P=0.26; RV end-diastolic pressure, 10.7±2.8 to 11.4±4.6 mm Hg, P=0.43). There was, however, a significant increase in PA diastolic pressure (10.1±3.6 to 15.4±7.6 mm Hg, P=0.001).

The median procedure time was 102 minutes (interquartile range, 67 to 124 minutes), and median fluoroscopy time was 21 minutes (range, 11 to 36 minutes). Five additional procedures were performed with PPVI (stenting of distal pulmonary arteries in 2, ventricular septal defect closure in 1, atrial septal defect closure in 1, and occlusion of paraprosthetic leak through a mechanical aortic valve in 1).

Echocardiography
Echocardiography performed 24 hours after PPVI showed a reduction in RV pressure as estimated from TR velocity (64±1.4 to 51.8±1.9 mm Hg, P<0.001) and RVOT gradient (63.4±23.4 to 40.5±18.2 mm Hg, P<0.001). There was significant reduction in grade of PR, with all patients having grade 2 or greater PR before, and none with more than grade 2 PR after the procedure (P<0.001).

Magnetic Resonance Imaging
Cardiovascular MRI was performed in 28 patients (age, 18.8±7.9 years; range, 9.2 to 41.6 years) a median of 6 days

### Table 1. Patient Demographics and Diagnosis

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Age, y (median) (range)</th>
<th>Weight, kg</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16 (9–43)</td>
<td>56 (25–110)</td>
<td>Tetralogy of Fallot variants</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TGA, VSD, PS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ross operation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Truncus arteriosus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>RVOT characteristics</td>
<td></td>
<td></td>
<td>Homograft (78%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hancock (8%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transannular patch (5%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other (8%)</td>
</tr>
</tbody>
</table>

TGA indicates transposition of great arteries; VSD, ventricular septal defect; and PS, pulmonary stenosis.

**Figure 2.** Hemodynamic parameters before and after pulmonary valve implantation. Pre- indicates before implantation; Post, after implantation; RVOT, RVOT gradient.

**Figure 3.** Lateral still-frame angiograms. Abolition of stenosis and regurgitation after pulmonary valve implantation.
before PPVI (range, 0 to 404 days) and a median of 6 days after the procedure (range, 1 to 64 days) (Table 2).

Sixty-one percent of the subjects (17/28) had a PR fraction of ≥20% (moderate or severe pulmonary regurgitation).

There was significant reduction in the PR fraction (21±13% to 3±4%, P<0.001) and RV end-diastolic volume (EDV) (94±28 to 82±24 mL · beat⁻¹ · m⁻², P<0.001) and a significant increase in RV effective SV (37±7 to 42±9 mL · beat⁻¹ · m⁻², P<0.006) after PPVI. RVEF did not change to 0.005) and LVSV (38±7 to 21±12 mL · beat⁻¹ · m⁻², P<0.001) and a significant increase in LVEDV (64±12 to 71±13 mL · beat⁻¹ · m⁻², P=0.005) and LVSV (38±7 to 23 mL · beat⁻¹ · m⁻², P=0.005). There was no significant change in the LVEF (63±10 to 64±9, P=0.45).

MRI was not possible in the entire cohort because of patients being referred from overseas; the presence of pacemakers, defibrillators, or stents preventing optimal imaging, or poor patient cooperation for breath-holding.

### Exercise Capacity

NYHA functional class improved after PPVI (median NYHA class, from 2 to 1, P<0.001) (Figure 5a). A subset of 16 consecutive patients, on cardiopulmonary exercise testing, had significant improvement in VO₂max (26±7 to 29±6 mL · kg⁻¹ · min⁻¹, P=0.006) (Figure 5b) and anaerobic threshold (14±4 to 16±3 mL · kg⁻¹ · min⁻¹, P=0.008) (Figure 5c).

### Predictors of Improvement in Exercise Capacity

The patients with improvement in their cardiopulmonary exercise had a significant reduction in PR fraction (17±13% to 3±3%, P<0.001) and RVEDV (95±25 to 84±23 mL · beat⁻¹ · m⁻², P<0.001) and a significant increase in LVEDV (65±11 to 74±14 mL · beat⁻¹ · m⁻², P=0.003) and effective RVSV (38±6 to 43±9 mL · beat⁻¹ · m⁻², P=0.048) (Table 3).

In 12 subjects, reduction in RVEDV was associated with improved VO₂max (Figure 6, a and b). In 2 subjects, RVEDV increased with worsening VO₂max. Both these subjects had predominantly stenotic lesions before PPVI (PR fraction = 1%)

### Table 2. MRI in Patients With PPVI

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, y</th>
<th>BSA, m²</th>
<th>Primary Diagnosis</th>
<th>Time From Before MRI to PPVI, d</th>
<th>Time From MRI to After MRI, d</th>
<th>Pulmonary RF Before PPVI, %</th>
<th>Peak Systolic Gradient Before PPVI, mm Hg</th>
<th>Metabolic Exercise Test Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15.2</td>
<td>1.6</td>
<td>ToF, pulm. atresia</td>
<td>0</td>
<td>3</td>
<td>20</td>
<td>67</td>
<td>\checkmark</td>
</tr>
<tr>
<td>2</td>
<td>12.5</td>
<td>1.3</td>
<td>TGA, ASO</td>
<td>11</td>
<td>3</td>
<td>20</td>
<td>60</td>
<td>\checkmark</td>
</tr>
<tr>
<td>3</td>
<td>18.8</td>
<td>1.6</td>
<td>ToF, pulm. atresia</td>
<td>4</td>
<td>1</td>
<td>38</td>
<td>27</td>
<td>\checkmark</td>
</tr>
<tr>
<td>4</td>
<td>14.4</td>
<td>1.6</td>
<td>AoV disease (Ross)</td>
<td>4</td>
<td>1</td>
<td>28</td>
<td>...</td>
<td>\checkmark</td>
</tr>
<tr>
<td>5</td>
<td>12.0</td>
<td>1.1</td>
<td>AoV disease (Ross)</td>
<td>4</td>
<td>1</td>
<td>28</td>
<td>58</td>
<td>\checkmark</td>
</tr>
<tr>
<td>6</td>
<td>11.7</td>
<td>1.2</td>
<td>TGA, ASO</td>
<td>4</td>
<td>1</td>
<td>22</td>
<td>44</td>
<td>\checkmark</td>
</tr>
<tr>
<td>7</td>
<td>25.7</td>
<td>1.6</td>
<td>ToF, pulm. stenosis</td>
<td>4</td>
<td>3</td>
<td>32</td>
<td>14</td>
<td>\checkmark</td>
</tr>
<tr>
<td>8</td>
<td>16.2</td>
<td>2.0</td>
<td>ToF, pulm. atresia</td>
<td>5</td>
<td>2</td>
<td>38</td>
<td>6</td>
<td>\checkmark</td>
</tr>
<tr>
<td>9</td>
<td>20.4</td>
<td>1.9</td>
<td>TGA, ASO</td>
<td>7</td>
<td>7</td>
<td>15</td>
<td>70</td>
<td>\checkmark</td>
</tr>
<tr>
<td>10</td>
<td>20.4</td>
<td>1.8</td>
<td>ToF, pulm. atresia</td>
<td>41</td>
<td>15</td>
<td>36</td>
<td>36</td>
<td>\checkmark</td>
</tr>
<tr>
<td>11</td>
<td>14.2</td>
<td>1.3</td>
<td>ToF, pulm. stenosis</td>
<td>404</td>
<td>17</td>
<td>40</td>
<td>2</td>
<td>\checkmark</td>
</tr>
<tr>
<td>12</td>
<td>13.4</td>
<td>1.6</td>
<td>Sub-pulm. stenosis</td>
<td>4</td>
<td>3</td>
<td>27</td>
<td>32</td>
<td>\checkmark</td>
</tr>
<tr>
<td>13</td>
<td>28.6</td>
<td>1.5</td>
<td>ToF, pulm. atresia</td>
<td>188</td>
<td>8</td>
<td>20</td>
<td>51</td>
<td>\checkmark</td>
</tr>
<tr>
<td>14</td>
<td>41.6</td>
<td>1.7</td>
<td>ToF, pulm. atresia</td>
<td>176</td>
<td>64</td>
<td>15</td>
<td>24</td>
<td>\checkmark</td>
</tr>
<tr>
<td>15</td>
<td>19.9</td>
<td>2.1</td>
<td>AoV disease (Ross)</td>
<td>97</td>
<td>8</td>
<td>33</td>
<td>36</td>
<td>\checkmark</td>
</tr>
<tr>
<td>16</td>
<td>14.7</td>
<td>1.8</td>
<td>ToF, pulm. stenosis</td>
<td>4</td>
<td>3</td>
<td>6</td>
<td>34</td>
<td>\checkmark</td>
</tr>
<tr>
<td>17</td>
<td>14.8</td>
<td>2.0</td>
<td>ToF, pulm. stenosis</td>
<td>4</td>
<td>3</td>
<td>27</td>
<td>32</td>
<td>\checkmark</td>
</tr>
<tr>
<td>18</td>
<td>15.7</td>
<td>1.6</td>
<td>TGA, ASO</td>
<td>225</td>
<td>2</td>
<td>10</td>
<td>71</td>
<td>\checkmark</td>
</tr>
<tr>
<td>19</td>
<td>38.4</td>
<td>2.0</td>
<td>AoV disease (Ross)</td>
<td>132</td>
<td>50</td>
<td>0</td>
<td>33</td>
<td>\checkmark</td>
</tr>
<tr>
<td>20</td>
<td>10.7</td>
<td>1.0</td>
<td>TGA, ASO</td>
<td>1</td>
<td>6</td>
<td>22</td>
<td>44</td>
<td>\checkmark</td>
</tr>
<tr>
<td>21</td>
<td>10.4</td>
<td>1.1</td>
<td>Common arterial trunk</td>
<td>1</td>
<td>6</td>
<td>28</td>
<td>23</td>
<td>\checkmark</td>
</tr>
<tr>
<td>22</td>
<td>22.0</td>
<td>1.7</td>
<td>ToF, pulm. atresia</td>
<td>286</td>
<td>15</td>
<td>10</td>
<td>52</td>
<td>\checkmark</td>
</tr>
<tr>
<td>23</td>
<td>24.0</td>
<td>2.2</td>
<td>ToF, pulm. atresia</td>
<td>1</td>
<td>1</td>
<td>24</td>
<td>51</td>
<td>\checkmark</td>
</tr>
<tr>
<td>24</td>
<td>12.5</td>
<td>1.2</td>
<td>Common arterial trunk</td>
<td>104</td>
<td>14</td>
<td>45</td>
<td>26</td>
<td>\checkmark</td>
</tr>
<tr>
<td>25</td>
<td>20.2</td>
<td>1.6</td>
<td>ToF, pulm. atresia</td>
<td>97</td>
<td>22</td>
<td>2</td>
<td>41</td>
<td>\checkmark</td>
</tr>
<tr>
<td>26</td>
<td>26.9</td>
<td>1.7</td>
<td>ToF, pulm. stenosis</td>
<td>50</td>
<td>55</td>
<td>4</td>
<td>34</td>
<td>\checkmark</td>
</tr>
<tr>
<td>27</td>
<td>20.3</td>
<td>2.1</td>
<td>AoV disease (Ross)</td>
<td>118</td>
<td>22</td>
<td>0</td>
<td>46</td>
<td>\checkmark</td>
</tr>
<tr>
<td>28</td>
<td>9.2</td>
<td>1.2</td>
<td>Common arterial trunk</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>59</td>
<td>\checkmark</td>
</tr>
</tbody>
</table>

BSA indicates body surface area; ToF, tetralogy of Fallot; pulm., pulmonary; TGA, transposition of the great arteries; ASO, arterial switch operation; and AoV, aortic valve.
and 12% before PPVI, respectively) and no significant increase in pulmonary regurgitation after PPVI (both <12%). In 2 other subjects, there was reduction in RVEDV but worsening of VO₂max after PPVI. Both had predominant pulmonary regurgitation (PR fraction 22%) that decreased significantly (12% and 6%) after PPVI, but they had residual pulmonary stenosis.

Exercise testing could not be performed in some patients because of poor co-operation or failure to achieve a maximal effort.

**Follow-Up**

The mean follow-up was 9.8±1.4 months and 100% complete for mortality and freedom from explantation. There was no mortality during the procedure or until the last follow-up.

Serial echocardiography showed that an early decrease in RVOT gradient was sustained at the latest follow-up (mean, 9.8 months) (63.4±23.4 to 48.8±24.2, P=0.006), despite some increase compared with that immediately after the procedure (40.5±18.2 to 48.8±24.2, P=0.06). The improvement in regurgitation was also sustained, with only 1 patient having moderate regurgitation because of endocarditis of the valve.

**Procedural Complications**

There were 3 significant early complications. In 2 patients, the stent dislodged over the guide wire, and both had successful surgical homograft implantation.

There was 1 life-threatening bleeding episode in a patient with a 16-mm homograft implanted during neonatal repair of truncus arteriosus. The stenotic and calcified homograft was predilated with a 16-mm balloon, which led to dissection of the homograft. We immediately proceeded to PPVI, with successful relief of obstruction. However, the patient developed hypotension and right hemothorax, requiring emergency right pleural drainage and autotransfusion to achieve hemodynamic stability. Surgical exploration was undertaken as an emergency procedure on femoral bypass, and sutures were placed on the homograft, with successful control of bleeding. An epicardial echocardiogram showed a well-functioning...
valve-stent implant, which was left in situ, with good hemodynamics.

There were 7 minor complications, which included minor dissection of the homograft \( n = 1 \) (treated conservatively), detachment of the distal tip of delivery system \( n = 2 \) into the branch PA, which was snared successfully and retrieved; and local bleeding \( n = 4 \), which was controlled without transfusion.

**Device-Related Adverse Events**

During the follow-up, there were device-related problems in 14 patients. In 7, in-stent stenosis was observed because of the “hammock effect” (Figure 7), in which the valve did not appose to the stent. Before recognition of this phenomenon, the device was explanted surgically in 3 patients. In explanted valves, there was no endothelial proliferation within the lumen or blood outside the venous wall. We believe that this was because of failure to suture the valve to the entire length of stent in the initial design of the device. There was probably a dynamic component to this mechanism that was seen better during angiography and may well be accentuated by a “Venturi” effect.

Subsequently, in 3 patients, a second stent was implanted within the first. One patient had relief of obstruction with just balloon dilatation of the “hammock” valve and is under close follow-up to watch for recurrence. The hammock effect was not observed after a change in the device design, when the whole length of the venous wall was sutured along the length of the stent.

Stent fracture was observed in 7 patients at a median of 9 months after PPVI. During meticulous follow-up, clinical problems were observed in 2. In 1 patient, the RVOT gradient increased, and the patient was successfully treated with a second valve implantation.

In the other, there was stent embolization to the right PA 9 months after the procedure. The patient presented with acute symptoms of chest pain and dyspnea. A chest radiograph revealed stent embolism to the right PA. An emergency cardiac catheterization was performed, and the stent was snared to be retrieved into the RVOT for surgical access to

**TABLE 3.** Metabolic Exercise Test and Ventricular Parameters on MRI in 16 Patients After PPVI

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before</th>
<th>After</th>
<th>Before vs After</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \dot{V}O_2 \text{max}, \text{mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} )</td>
<td>26±7 (16–35)</td>
<td>29±6 (15–40)</td>
<td>0.006</td>
</tr>
<tr>
<td>Anaerobic threshold, ( \text{mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1} )</td>
<td>14±4 (10–24)</td>
<td>16±3 (10–22)</td>
<td>0.008</td>
</tr>
<tr>
<td>RV EDV, ( \text{mL} \cdot \text{beat}^{-1} \cdot \text{m}^{-2} )</td>
<td>95±25 (68–150)</td>
<td>84±23 (46–136)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LV EDV, ( \text{mL} \cdot \text{beat}^{-1} \cdot \text{m}^{-2} )</td>
<td>65±11 (46–85)</td>
<td>74±14 (55–105)</td>
<td>0.003</td>
</tr>
<tr>
<td>Corrected RV SV, ( \text{mL} \cdot \text{beat}^{-1} \cdot \text{m}^{-2} )</td>
<td>38±6 (30–51)</td>
<td>43±9 (31–61)</td>
<td>0.048</td>
</tr>
<tr>
<td>PR fraction, %</td>
<td>17±13 (0–45)</td>
<td>3±3 (0–7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peak systolic gradient, mm Hg</td>
<td>39±13 (23–71)</td>
<td>22±14 (9–60)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

\[ \text{Figure 5.} \] a. NYHA classification before and after PPVI. Maximal oxygen consumption (\( \dot{V}O_2 \text{max} \)) (b) and anaerobic threshold (c) before and after PPVI.
explain the device, and a valved conduit was successfully implanted, with good outcome. In the remaining patients who required explantation, a major indication was residual stenosis caused by either external compression of the conduit despite the presence of the stent or residual stenosis because of inability to deploy the device fully at implantation, 1 of them associated with intravascular hemolysis.

One patient developed endocarditis after a dental procedure without antibiotic prophylaxis and required explantation for failure of medical therapy.

The freedom from explantation for valve failure was 89% (95% CI, 80% to 97%) at 6 months, 83.3% (69.5% to 97.2%) at 12 months, 79.7% (67.2% to 92.2%) at 24 months, and 69.8% (48.4% to 91.1%) at 36 months (Figure 8).

**Discussion**

Repair and reconstruction of RVOT has been undertaken with increasing success during corrective surgery for congenital heart disease; however, a significant number of patients have residual lesions. Pulmonary regurgitation is increasingly recognized as the major determinant of long-term morbidity and mortality in patients who had surgery on RVOT.13,17–20 RVOT dysfunction forms a major indication for reoperation in an adult congenital heart unit, and multiple operations are anticipated and performed.7

Stenosis has been accessible to interventional catheterization21,22 with balloon dilatation and stent implantation with good early and mid-term relief of obstruction. This approach has been very effective in treating conduit stenosis not involving the valve leaflets. PPVI represents an important advance, because it deals successfully with both stenosis and regurgitation components of RVOT dysfunction. We have clearly shown a significant and sustained improvement in RV hypertension with relief of RVOT gradient in the subgroup of patients with predominant stenosis, with no significant regurgitation after PPVI. Furthermore, a significant and sustained improvement in pulmonary regurgitation was also achieved in the subgroup with predominant regurgitation.

![Figure 6](image-url)

**Figure 6.** a. Plot of change in RVEDV against change in VO2max. b. Plot of change in RVSV against change in VO2max.

![Figure 7](image-url)

**Figure 7.** “Hammock” effect (arrows). The venous wall hanging in the stent causing stenosis.

![Figure 8](image-url)

**Figure 8.** Kaplan-Meier plots for freedom from surgical explantation after transcatheter pulmonary valve implantation. Numbers on x axis indicates patients at risk during follow-up.
We observed 3 separate categories of complications. The first were complications related to balloon dilatation or stenting for conduit stenosis, including dissection, hemorrhage from conduit rupture, and residual stenosis because of external compression or undilatable conduits.21–23

The second category was related to issues of patient selection and occurred in the new substrate of patients with predominant regurgitation who have previously been accessible to interventional catheterization. Dislodgment or embolization of the valve stent during PPVI or follow-up occurred because of unfavorable shape, size, and elastic properties of the RVOT. Understanding wall characteristics and 3D dynamic imaging of RVOT would refine patient selection and is a key issue of current research by our group.

The third category, related to device design, included the “hammock” effect and stent fracture. The hammock effect was resolved during the series with an improved design, whereby the entire length of the stent was sutured to the venous wall segment. In one series, 16% of patients had stent fractures in RV to PA conduits.22 In our series, 12% of patients had stent fracture; however, only 2 had clinical consequences. One was treated with a second PPVI with a successful hemodynamic result. The other patient with stent embolism has been described in the earlier section.

Transcatheter pulmonary valve replacement provides a unique opportunity to study the response of the RV to acute pressure and volume unloading without the confounding effect of cardiopulmonary bypass. Previous studies after surgical pulmonary valve replacement have shown reduction in RVEDVs (MRI)12 and RV dimensions (echocardiography),11 and both improved subjectively11,12 and objectively (metabolic exercise testing),24 although no association between changes in ventricular parameters and exercise capacity has been shown.

Cardiovascular MRI assessment in patients with severe pulmonary regurgitation has demonstrated markedly elevated RVEDV and RVESV and reduced RVEF.25–28 This chronic RV volume overload has long been regarded as benign, but pulmonary regurgitation has demonstrated markedly elevated EF,11 and both improved subjectively11,12 and objectively (metabolic exercise testing),24 although no association between changes in ventricular parameters and exercise capacity has been shown.

Transcatheter pulmonary valve replacement provides a unique opportunity to study the response of the RV to acute pressure and volume unloading without the confounding effect of cardiopulmonary bypass. Previous studies after surgical pulmonary valve replacement have shown reduction in RVEDVs (MRI)12 and RV dimensions (echocardiography),11 and both improved subjectively11,12 and objectively (metabolic exercise testing),24 although no association between changes in ventricular parameters and exercise capacity has been shown.

In our study, there was a reduction in RVEDV and improved performance at metabolic exercise testing (12 of 16 subjects), and in 2 subjects in whom RVEDV increased, there was reduced performance at metabolic exercise test (both predominant stenosis patients). The reduction in RVEDV was associated with an increase in LVEDV, which suggests that the mechanism of clinical improvement may be related to diastolic ventricular interaction.31 We propose that reduction in RVEDV after reduction in PR volume by valve implantation permits an increase in LV filling and thus LVEDV. This occurs within the constraints of the pericardial space and, by the Frank-Starling mechanism, results in an increase in stroke volume, which may be responsible for the subjective and objective improvements in functional status. This mechanism is further supported by evidence in patients with heart failure, which suggests that abnormalities of LV diastolic function are a key determinant of exercise intolerance.32 A second explanation for the improved LV filling may simply be related to increased effective RSVV as a result of a reduction in RVOT obstruction, thus increasing pulmonary venous return, left atrial filling, and LV preload. Further studies are in progress to define the mechanism of ventricular interaction.

Limitations
Although we have demonstrated an immediate beneficial effect of PPVI, long-term follow-up will be essential to evaluate the potential for ventricular remodeling and sustained symptomatic relief. The subjects in this study were heterogeneous in terms of age, diagnosis, RVOT pathology, RV dilatation, and RV function.

As with all new procedures, whether surgical or interventional, we recognize the impact of learning curve on this novel technique. The reintervention and explantation rates may appear to be higher in direct comparison to surgical reports; however, evolution of device design and more experience have led to further a decrease, and indeed elimination, of some of the early problems. Also, our cohort of patients is complex, with a median of 3 operations on their RVOT before the PPVI. Despite this, and including the whole series right from the first case, there has been no mortality, either during the procedure or during late follow-up.

The patient population in our series had distinct RVOT dimensions and morphology favorable for implantation of the valve stent. We are working to expand this application to patients with dilated RVOTs with development of RVOT reducers. MRI and cardiopulmonary exercise testing could not be obtained in the entire cohort of patients.

Summary
Our PPVI program is the first clinical step in treatment of valvular regurgitation in the modern era of transcatheter therapeutics. This approach will alter strategies for transcatheter management of other heart valves and lead to a major change in the lifetime management of patients with congenital heart disease.

Acknowledgments
Dr Taylor was funded by the Higher Education Funding Council for England (HEFCE). Drs Coats, Boudjemline, Deanfield, and Bonhoeffer were funded by the British Heart Foundation. Drs Razavi, Muthurangu, and Hegde were funded by the HEFCE Joint Research Equipment Initiative; Philips Medical Systems, Best, the Netherlands; the Evelina Trust; and the Charitable Foundation of Guy’s and St Thomas NHS Trust.

Disclosure
Dr Bonhoeffer is a consultant to Medtronic.
References


Percutaneous Pulmonary Valve Implantation in Humans: Results in 59 Consecutive Patients
Sachin Khambadkone, Louise Coats, Andrew Taylor, Younes Boudjemline, Graham Derrick, Victor Tsang, Jeffrey Cooper, Vivek Muthurangu, Sanjeeet R. Hegde, Reza S. Razavi, Denis Pellerin, John Deanfield and Philipp Bonhoeffer

Circulation. 2005;112:1189-1197; originally published online August 15, 2005; doi: 10.1161/CIRCULATIONAHA.104.523266

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/112/8/1189

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/